Corline Biomedical AB (CLBIO) - Total Liabilities
Based on the latest financial reports, Corline Biomedical AB (CLBIO) has total liabilities worth Skr15.18 Million SEK (≈ $1.63 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CLBIO asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Corline Biomedical AB - Total Liabilities Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Corline Biomedical AB.
Corline Biomedical AB Competitors by Total Liabilities
The table below lists competitors of Corline Biomedical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IHQ Inc
KO:003560
|
Korea | ₩40.85 Billion |
|
Zaklady Przemyslu Cukierniczego Otmuchow S.A.
WAR:OTM
|
Poland | zł64.22 Million |
|
Novacyt
PA:ALNOV
|
France | €16.94 Million |
|
WT Financial Group Ltd
AU:WTL
|
Australia | AU$26.32 Million |
|
Chih Lien Industrial Co Ltd
TW:2024
|
Taiwan | NT$495.04 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
Israel | ILA6.32 Million |
|
Edesa Biotech Inc
NASDAQ:EDSA
|
USA | $3.91 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Corline Biomedical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CLBIO net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Corline Biomedical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Corline Biomedical AB (2012–2025)
The table below shows the annual total liabilities of Corline Biomedical AB from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr4.82 Million ≈ $518.60K |
-38.60% |
| 2024-12-31 | Skr7.85 Million ≈ $844.57K |
+15.60% |
| 2023-12-31 | Skr6.79 Million ≈ $730.60K |
-5.63% |
| 2022-12-31 | Skr7.19 Million ≈ $774.19K |
-23.69% |
| 2021-12-31 | Skr9.43 Million ≈ $1.01 Million |
+50.83% |
| 2020-12-31 | Skr6.25 Million ≈ $672.60K |
+40.99% |
| 2019-12-31 | Skr4.43 Million ≈ $477.06K |
-44.26% |
| 2018-12-31 | Skr7.95 Million ≈ $855.87K |
+44.57% |
| 2017-12-31 | Skr5.50 Million ≈ $592.00K |
+117.52% |
| 2016-12-31 | Skr2.53 Million ≈ $272.16K |
-32.46% |
| 2015-12-31 | Skr3.74 Million ≈ $402.98K |
-66.83% |
| 2014-12-31 | Skr11.29 Million ≈ $1.21 Million |
+95.96% |
| 2013-12-31 | Skr5.76 Million ≈ $619.91K |
-48.05% |
| 2012-12-31 | Skr11.09 Million ≈ $1.19 Million |
-- |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent ha… Read more